Delving into the Latest Updates on Ancestim with Synapse

Overview

Basic Info

Drug Type

Colony-stimulating factors

Synonyms

Ancestim (USAN/INN), Ancestim (genetical recombination) (JAN), Human SCF

+ [5]

Target

CSF-3R

Action

agonists, stimulants

Mechanism

CSF-3R agonists(Colony stimulating factor 3 receptor agonists), Stem cells stimulants

Therapeutic Areas

Other Diseases

Active Indication

Hematopoietic stem cell transplantation

Inactive Indication-

Originator Organization

Amgen, Inc.

Active Organization

Amgen, Inc.

Inactive Organization-

License Organization

Amgen, Inc.

Swedish Orphan Biovitrum AB

Drug Highest PhaseApproved

First Approval Date

Australia (09 Aug 1999),

Hematopoietic stem cell transplantation

RegulationOrphan Drug (United States)

Login to view timeline

Structure/Sequence

Sequence Code 16915307

Source: *****

Some drugs have the ability to push stem cells (the cells responsible for producing new cell types) out of the bone marrow and into the blood stream. The steps involved in this process are still poorly understood. However, a better understanding of this process could lead to improved results in transplantation, cancer treatment, and contribute to the development of new genetic therapies for a wide variety of disorders.
In this study researchers plan to compare two different treatments, both that mobilize (push) stem cells out of the bone marrow into the blood stream. In addition, researchers will attempt to determine which is the most efficient at mobilizing blood cells of patients with multiple myeloma.
Information and knowledge gained from this study will help to design future transplantation and genetic therapy research studies.

Start Date01 Sep 1998

Sponsor / Collaborator

National Heart, Lung & Blood Institute

100 Clinical Results associated with Ancestim

Login to view more data

100 Translational Medicine associated with Ancestim

Login to view more data

100 Patents (Medical) associated with Ancestim

Login to view more data

966

Literatures (Medical) associated with Ancestim

23 Apr 2025·Acta Microbiologica et Immunologica Hungarica

Antibacterial efficacy of cefoperazone/sulbactam in combination with various antimicrobials against carbapenem-resistant Klebsiella pneumoniae

Article

Author: Xu, Chunlai

AbstractCarbapenem-resistant Klebsiella pneumoniae (CRKP) is one of the major Gram-negative bacteria in human infections, which can cause pneumonia, sepsis, meningitis, and abscess. However, the current therapy for CRKP infection is polymyxin and tigecycline. The aim of this study is to analyze the in vitro antibacterial effects of cefoperazone/sulbactam (SCF) combined with ceftazidime (CAZ), imipenem/cilastatin (IMI), and meropenem (MEM) against CRKP harbouring different antibiotic resistance genes. In this study, fifteen clinical isolates of CRKP from January to December 2023 were taken from our hospital for bacterial identification and confirmation of carbapenemase genotypes, and the minimum inhibitory concentration (MIC) of SCF, CAZ, IMI, and MEM were determined by broth microdilution method. The results of combined drug sensitivity test were determined by checkerboard method and characterized with fractional inhibitory concentration (FIC). The combined antibacterial activity was determined by time-kill curve. The results showed that among the 15 CRKP strains, 9 carried blaKPC gene, 3 carried blaNDM gene and 3 carried blaOXA-48-like gene. The MIC values determined by broth microdilution method showed better sensitivity of KPC-producing CRKP to four antimicrobial drugs including SCF. However, blaNDM as well as blaOXA-48-like genotypes showed strong resistance to all four antimicrobial drugs. The FIC values of SCF combined with CAZ, IMI and MEM showed that all tested antibacterial agents had the best effect on KPC-producing CRKP, and had no obvious additive effect on other CRKP. The results of time-kill curve showed that SCF combined with IMI had good antibacterial effect. This study found that SCF combined with IMI has a synergistic antibacterial effect on KPC producing carbapenem-resistant K. pneumoniae, which could provide reference for clinical practice.

28 Mar 2025·Medicine

Septicemia caused by Eikenella corrodens in a previously healthy male: A case report

Article

Author: Xia, Yongfu ; Zhang, Haoting ; Wang, Linhong ; Zhang, Bin

Rationale:The bacterium Eikenella corrodens is part of the normal microbiota of the oropharynx. It typically causes disease in patients with bite wound, immunosuppression, and those undergoing surgery, but rarely affects healthy individuals. Despite the rarity of infection induced by E corrodens, early diagnosis and therapy are important.Patient concerns:The study reports a case of septicemia caused by E corrodens in a previously healthy male individual. The patient was admitted to hospital due to fever, fatigue, and mild cough lasting 4 weeks. Physical examination was unremarkable. Chest and abdominal computed tomography showed no obvious infiltrates. Transthoracic echocardiography did not reveal excrescence on the aortic valve.Diagnoses:E corrodens was isolated from blood, proving its pathogenic potential. To confirm the pathogen, 16S rRNA gene sequencing was performed directly from the blood culture, obtaining a sequence that aligned with E corrodens with a homology percentage of 99.8%. The patient was diagnosed as septicemia caused by E corrodens.Interventions:The patient was treated with moxifloxacin (0.4 g once daily) intravenously for 3 days, but continued to experience recurrent fever. Following the diagnosis of septicemia caused by E corrodens, antibiotic treatment was switched to cefoperazone-sulbactam (SCF; 3 g every 8 h) for 14 days in total.Outcomes:Fever, fatigue, and other discomfort were relieved after 1 day of treatment with SCF. The white blood cell count, C-reactive protein concentration, and procalcitonin levels were gradually normalized after 14 days of treatment with SCF. Blood culture was performed after 14 days of treatment with SCF, yielding negative results.Lessons:The present case report highlights that E corrodens should be considered as a cause of septicemia even in healthy individuals. For the avoidance of delayed diagnosis, it is vital to perform blood culture before initiating antibiotic treatment. Furthermore, SCF should be considered as a preferred treatment option for such infections.

01 Mar 2025·Food Science and Biotechnology

Fermentation characteristics and anti-hypolipidemic effect of barley wine from co-fermentation with yeast and lactic acid bacteria

Article

Author: Song, Geun-Seoup ; Oh, Hyeon Hwa ; Jeong, Do-Youn ; Jang, So-Won

In this study, the variations in ingredients (organic acid, free sugar, free amino acid, β-glucan, γ-aminobutyric acid (GABA), total phenolic content (TPC)) of single yeast fermentation (SYF0d, SYF5d, SYF10d) and simultaneous cultured fermentation (SCF0d, SCF5d, SCF10d) were analyzed. The contents of β-glucan, GABA, and TPC in SCF10d were higher compared to those in SYF10d (417.28, 596.77, and 495.66 μg/mL), at 1158.92, 818.57, and 605.48 μg/mL, respectively. DPPH radical activity, ABTS radical activity, and oxygen radical absorbance capacity were greater in SCF10d than in SYF10d (187.60, 885.58, and 1.98 mg/mL), at 506.05, 1674.90, and 2.73 mg/mL, respectively. Anti-hypolipidemic (ACE1 inhibitory activity) and anti-cholesterol (HMG-CoA reductase inhibitory activity) of SCF10d were 59.66% (1/5 dilution factor, DF) and 37.16% (1/10 DF), respectively. These results suggest that SCF had higher antioxidant and anti-hypolipidemic activities.

100 Deals associated with Ancestim

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D02937	Ancestim	L03AA12	DB09103

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Hematopoietic stem cell transplantation	Australia	Amgen, Inc.	09 Aug 1999

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASCO2004	Not Applicable	Relapsed Solid Neoplasm	-	rhTPO	(useuvohryt) = enqgplodwo ihrazvdaoq (dqhzlcfxio ) View more	-	15 Jul 2004
				rhIL-11 + G-SCF	(useuvohryt) = xouslxrbjb ihrazvdaoq (dqhzlcfxio ) View more

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data